Review
Dermatology
Aaminah Azhar, Marcus Zaayman, Annika Silfvast-Kaiser, Dario Kivelevitch, Alan Menter, So Yeon Paek
Summary: Ixekizumab is a humanized monoclonal antibody approved for plaque psoriasis treatment, demonstrating superiority in clinical trials with no significant difference in side effects. Chronicity of psoriasis requires continual treatment for disease clearance.
DERMATOLOGIC THERAPY
(2021)
Article
Medicine, General & Internal
Kenneth B. Gordon, Peter Foley, James G. Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi, Andrew Blauvelt
Summary: The study demonstrated that Bimekizumab showed high levels of response in patients with moderate to severe plaque psoriasis, with durable effects over 56 weeks under both maintenance dosing schedules (every 4 weeks and every 8 weeks). Additionally, Bimekizumab was well tolerated with no unexpected safety issues, further supporting its therapeutic value for this patient population.
Review
Pediatrics
Hannah A. Blair
Summary: Subcutaneous secukinumab is an effective treatment option for children and adolescents with moderate to severe plaque psoriasis, providing fast and durable skin clearance, continuous improvement in health-related quality of life, and long-term maintained benefits.
Article
Dermatology
Nina Magnolo, Kulli Kingo, Vivian Laquer, John Browning, Adam Reich, Jacek C. Szepietowski, Deborah Keefe, Rafal Mazur, Prayashi Ghelani, Pascal Forrer, LindaAnn Wraith, Manmath Patekar
Summary: The study evaluated the efficacy and safety of two secukinumab dosage regimens in pediatric patients with moderate to severe plaque psoriasis, showing both doses were superior to historical placebo and well tolerated by the patients.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2022)
Article
Dermatology
Melinda J. Gooderham, Charles Lynde, Irina Turchin, Miriam Avadisian, Melanie Labelle, Kim A. Papp
Summary: The study evaluated the time to first biologic treatment change in Canadian patients with moderate-to-severe chronic plaque PsO, finding that approximately half of the patients required a treatment change (mainly interval change or biologic switch) while the other half remained on treatment.
JOURNAL OF DERMATOLOGY
(2022)
Review
Oncology
Yuxiong Jiang, Youdong Chen, Qian Yu, Yuling Shi
Summary: Psoriasis is a systemic immune-mediated disease associated with increased risk of multiple comorbidities. With the introduction of biological agents, the efficacy and safety of psoriasis treatments have greatly improved. Different classes of drugs, including tumor necrosis factor-alpha inhibitors, interleukin-17 inhibitors, and small-molecule inhibitors, have been approved for the treatment of moderate-to-severe psoriasis. These drugs not only target psoriasis but also have significant effects on its comorbidities. Understanding the characteristics of these drugs can provide personalized care for patients with distinct comorbidities.
Article
Immunology
Chen Yu, Furen Zhang, Yangfeng Ding, Yumei Li, Yi Zhao, Jun Gu, Shuping Guo, Weili Pan, Hongzhong Jin, Qing Sun, Xiaojing Kang, Qinping Yang, Xian Jiang, Zhiqiang Song, Qianjin Lu, Xiaowen Pang, Yehong Kuang, Danqi Deng, Yuzhen Li, Chunlei Zhang, Juan Tao, Liangzhi Xie, Yan Wang, Jieying Wang, Gang Wang
Summary: This study compares the efficacy, safety, and immunogenicity of SCT630 and adalimumab in Chinese patients with moderate to severe plaque psoriasis. The results demonstrate the equivalence of SCT630 and adalimumab in terms of efficacy, safety, and immunogenicity.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Ran Pan, Xiaolun Wang, Min Shu, Jaydeep Das, Manik Kalra, Zhidong Wang
Summary: The efficacy of SEC in the treatment of patients with moderate-to-severe plaque psoriasis is well demonstrated through NMA.
CHINESE MEDICAL JOURNAL
(2022)
Article
Medicine, General & Internal
Kristian Reich, Kim A. Papp, Andrew Blauvelt, Richard G. Langley, April Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Madden, Maggie Wang, Christopher Cioffi, Veerle Vanvoorden, Mark Lebwohl
Summary: Bimekizumab was more effective than ustekinumab and placebo in the treatment of moderate to severe plaque psoriasis, with a safety profile consistent with previous studies.
Article
Dermatology
Jensen Yeung, Marc Bourcier, Melinda J. Gooderham, Parbeer Grewal, Chih-Ho Hong, Perla Lansang, Charles Lynde, Catherine Maari, Vimal H. Prajapati, Irina Turchin, Ron Vender
Summary: A group of Canadian dermatologists convened to develop a consensus statement for treating moderate-to-severe plaque psoriasis using biologics. They proposed a multidimensional approach to defining treatment targets and a criterion-based system for determining treatment success.
DERMATOLOGIC THERAPY
(2022)
Article
Medicine, General & Internal
Alexander Egeberg, Joseph F. Merola, Knut Schaekel, Luis Puig, Patrick D. Mahar, Isabella Yali Wang, Imre Pavo, Christopher Schuster, Christopher E. M. Griffiths
Summary: Patients with psoriasis and prediabetes or type 2 diabetes experience similar efficacy in the treatment of moderate-to-severe psoriasis with ixekizumab. Type 2 diabetes may delay the achievement of complete clearance of psoriasis lesions in patients receiving ixekizumab treatment.
FRONTIERS IN MEDICINE
(2023)
Review
Pharmacology & Pharmacy
Laura Calabrese, Dalma Malvaso, Flaminia Antonelli, Maria Mannino, Ketty Peris, Andrea Chiricozzi
Summary: This review aims to explore new therapeutic strategies and novel drugs currently in development for the treatment of psoriasis, primarily focusing on agents in phase I/II of clinical development. Some of these drugs build upon existing therapeutic approaches, such as inhibition of the IL23/Th17 pathway, while others introduce new and unexplored methods.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Dermatology
Kim Papp, Carle Paul, C. Elise Kleyn, Yu-Huei Huang, Tsen-Fang Tsai, Christopher Schuster, Celine El Baou, Agoston Toth, Elisabeth Riedl, Ulrich Mrowietz
Summary: This study analyzes the time to loss of treatment response in psoriasis patients who responded to ixekizumab during a 12-week treatment period and were then re-randomized to placebo for 48 weeks. The results show that some patients maintain treatment response even after treatment interruption, and a subset of patients maintain high levels of disease control for up to 60 weeks.
ACTA DERMATO-VENEREOLOGICA
(2022)
Article
Dermatology
Jian Zhou, Yuan Yuan, Yanhua Liu, Mengyang Chu, Huan Liu, Qian Liu, Rui Wang, Shuai Shao, Gang Wang, Chen Yu
Summary: A single-arm observational study including 254 Chinese psoriatic patients treated with secukinumab demonstrated its high effectiveness and safety. The study showed that at 52 weeks, the PASI 75, PASI 90, and PASI 100 response rates in the 300 mg secukinumab group were 94.5%, 74.5%, and 47.6%, respectively.
EXPERIMENTAL DERMATOLOGY
(2023)
Review
Biotechnology & Applied Microbiology
Jennifer Clay Cather, Chaney T. Young, Melody S. Young, J. Christian Cather
Summary: This review summarizes the use of Ixekizumab in pediatric patients with moderate to severe plaque psoriasis, highlighting its role as the only IL17 antagonist for pediatric psoriasis. Its approval in the US and EU has added a valuable option to our treatment arsenal based on phase 3 trial data and clinical experience.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2021)
Article
Dermatology
Luvneet Verma, Julia N. Mayba, Melinda J. Gooderham, Ankush Verma, Kim A. Papp
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
(2018)
Review
Dermatology
Charles W. Lynde, Marc Bourcier, Melinda Gooderham, Lyn Guenther, Chih-ho Hong, Kim A. Papp, Yves Poulin, Gordon Sussman, Ronald Vender
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
(2018)
Review
Dermatology
Melinda Gooderham, Julian McDonald, Kim Papp
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
(2018)
Article
Dermatology
A. Blauvelt, K. A. Papp, H. Sofen, M. Augustin, G. Yosipovitch, N. Katoh, U. Mrowietz, M. Ohtsuki, Y. Poulin, D. Shrom, R. Burge, K. See, L. Mallbris, K. B. Gordon
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2017)
Article
Dermatology
K. A. Papp, M. J. Gooderham, G. Girard, M. Raman, V. Strout
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2017)
Article
Dermatology
A. Nast, P. I. Spuls, G. van der Kraaij, P. Gisondi, C. Paul, A. D. Ormerod, P. Saiag, C. H. Smith, E. Dauden, E. M. de Jong, E. Feist, R. Jobling, M. Maccarone, U. Mrowietz, K. A. Papp, K. Reich, S. Rosumeck, T. Talme, H. B. Thio, P. van de Kerkhof, R. N. Werner, C. Dressler
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2017)
Article
Dermatology
K. A. Papp, C. L. Leonardi, A. Blauvelt, K. Reich, N. J. Korman, M. Ohtsuki, C. Paul, S. Ball, G. S. Cameron, J. Erickson, L. Zhang, L. Mallbris, C. E. M. Griffiths
BRITISH JOURNAL OF DERMATOLOGY
(2018)
Article
Dermatology
Kim A. Papp, Marc Bourcier, Yves Poulin, Charles W. Lynde, Martin Gilbert, Melanie Poulin-Costello, Lieven Billen, Maya Isaila
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
(2018)
Article
Dermatology
Mark G. Lebwohl, Kim A. Papp, Lauren B. Marangell, John Koo, Andrew Blauvelt, Melinda Gooderham, Jashin J. Wu, Shipra Rastogi, Susan Harris, Radhakrishnan Pillai, Robert J. Israel
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2018)
Article
Dermatology
Boni E. Elewski, Martin M. Okun, Kim Papp, Christopher S. Baker, Jeffrey J. Crowley, Gerard Guillet, Murali Sundaram, Yves Poulin, Yihua Gu, Ziqian Geng, David A. Williams, Phoebe A. Rich
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
(2018)
Review
Dermatology
M. J. Gooderham, K. A. Papp, C. W. Lynde
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2018)
Article
Economics
Kim A. Papp, Min Yang, Murali Sundaram, John Jarvis, Keith A. Betts, Yanjun Bao, James E. Signorovitch
Article
Dermatology
Linda Stein Gold, Kim Papp, Charles Lynde, Edward Lain, Melinda Gooderham, Sandra Johnson, Nabil Kerrouche
JOURNAL OF DRUGS IN DERMATOLOGY
(2017)
Article
Dermatology
J. Bagel, S. Tyring, K. C. Rice, D. H. Collier, G. Kricorian, J. Chung, J. Iles, B. S. Stolshek, A. Kaliyaperumal, K. A. Papp
BRITISH JOURNAL OF DERMATOLOGY
(2017)
Article
Allergy
Hermenio Lima, Melinda Gooderham, Jan Dutz, Charles Lynde, Hugo Chapdelaine, Anne Ellis, Martin Gilbert, Vincent Ho, Kim Papp, Yves Poulin, Gordon Sussman
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY
(2017)